In a study trial, pharmaceutical giant Eli Lilly's weight-loss drug Zepbound showed better results than another pharmaceutical company, Novo Nordisk's weight-loss drug Wegovy. The trial, called SURMOUNT-5, compared Zepbound to Wegovy, which is a mono GLP-1 receptor agonist in adults living with obesity without diabetes. The results showed Zepbound delivering a remarkable 47% greater relative weight loss compared to Wegovy, …
Drugmakers and pharmacists battle over who gets to make obesity drugs toggle caption James Manning/PA Images/Getty Images Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high demand that the drugmakers have had a hard time keeping up. "Everybody knows that… injections are going to come off the shortage list eventually and patients need to …
